REG - AstraZeneca PLC - Total Voting Rights

AstraZenecaAnnouncement

03/02/2020 15:00

RNS Number : 7786B
AstraZeneca PLC
03 February 2020
 


03 February 2020 15:00 GMT
 
 
Transparency Directive
Voting Rights and Capital
 
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 2020 the issued share capital of AstraZeneca PLC with voting rights is 1,312,187,447 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,312,187,447.
 
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
 
 
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.



Media Relations












Gonzalo Viña






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Angela Fiorin


BioPharmaceuticals


+44 1223 344 690




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals
(Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)


+44 203 749 5631




Tom Waldron


Other medicines


+44 7385 033 717




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRFLFEFFSIVIII